These data represent a potential mechanism for TopoIIα drug resistance and suggest that inhibiting the activity of geminin and TopoIIα, CKIε and/or Cdc7 can be more beneficial for breast cancer patients with aggressive, drug-resistant disease. Here, CDC7 is linked to breast cancer.